Celtaxsys Inc., a privately-held biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders through innate immunity, today announced that Mr. Khalil Barrage has been appointed to the Board of Directors.
“As a as a major healthcare investor, Khalil brings a depth of experience and expertise to our leadership team. We are pleased that he has chosen to join Celtaxsys as the Company moves its lead compound, CTX-4430, through clinical development,” said Dr. Michael R. Hanley, CEO and Chairman.
